Endometrium Cancer Clinical Trial
Official title:
Weight Management in Overweight Endometrial Cancer Patients Undergoing Fertility-sparing Treatment
In this study, overweight and obese patients with endometrial cancer treated with fertility- sparing therapy were randomly divided into two groups. The test group was given weight management, while the control group was given routine care. Relevant information such as body morphology and composition, glycolipid metabolism, molecular typing and tumor outcomes of the subjects were collected. By evaluating the tumor outcome and changes in glycolipid metabolism indicators, to confirm the effectiveness and safety of weight management for overweight and obese patients with endometrial cancer and treatd with fertility preservation.
Obesity is recognized as a major risk factor for the development of endometrial cancer. Notably, several retrospective studies have shown that obesity reduces complete remission and pregnancy rates and increases recurrence rates in patients with endometrial cancer and atypical hyperplasia who undergo fertility-sparing treatment. Guidelines or consensus statements for fertility-sparing treatment in endometrial cancer recommend weight management. However, prospective intervention studies on the effectiveness of systematic weight management models in patients receiving reproductive function-preserving treatment for endometrial cancer and atypical hyperplasia are lacking. This study therefore aimed to investigate the impact of the weight management on body morphology and composition, glycolipid metabolism, and tumor outcomes in overweight and obese patients with endometrial cancer and atypical hyperplasia who underwent reproductive function-preserving treatments.In this study, overweight and obese patients with endometrial cancer treated with fertility- sparing therapy were randomly divided into two groups. The test group was given weight management, while the control group was given routine care. Relevant information such as body morphology and composition, glycolipid metabolism, molecular typing and tumor outcomes of the subjects were collected. By evaluating the tumor outcome and changes in glycolipid metabolism indicators, to confirm the effectiveness and safety of weight management for overweight and obese patients with endometrial cancer and treatd with fertility preservation. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05036681 -
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
|
Phase 2 | |
| Completed |
NCT00377520 -
A Trial for Patients With Advanced/Recurrent Endometrial Cancer
|
Phase 2 | |
| Recruiting |
NCT05902988 -
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06192017 -
Development of a Molecular Diagnostic Tool for Endometrial Cancer.
|
||
| Completed |
NCT03899441 -
Multimedia Aid Gynecologic Counseling and Consent
|
N/A | |
| Completed |
NCT02552121 -
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT02001623 -
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT02997553 -
Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery
|
Phase 3 | |
| Suspended |
NCT03095664 -
Effect of a Lifestyle Intervention on Nutritional Status and Prognosis of Endometrial Cancer Survivors
|
N/A | |
| Active, not recruiting |
NCT01466777 -
Endometrial Cancer and Robotic-assisted Versus Traditional Laparoscopy
|
N/A | |
| Completed |
NCT01068483 -
Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients
|
Phase 1 | |
| Recruiting |
NCT03896113 -
Neoadjuvant Celecoxib in Newly Diagnosed Patients With Endometrial Carcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT03570866 -
PET/CT in the Management of Patients With Early Stage Endometrial Cancer
|
||
| Completed |
NCT05246462 -
The Effect of Logotherapy on Mental Health in Gynecological Cancer Patients
|
N/A | |
| Withdrawn |
NCT04464967 -
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05651282 -
Risk Evaluation and Screening to Tailor Prevention and Reduce the Incidence of Endometrial Cancer
|
Phase 4 | |
| Completed |
NCT06187558 -
Suspension of the Pelvic and Abdominal Organs During Minimally Invasive Surgery
|
||
| Completed |
NCT06312917 -
Effect of Physical Activity Intervention on Overweight and Obese Patients With Endometrial Cancer
|
N/A | |
| Active, not recruiting |
NCT03951415 -
Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer
|
Phase 2 | |
| Recruiting |
NCT04212910 -
Stratifying Endometrial Cancer Patients Using a PET/MRI Prognostic Model
|